Bristol Myers Squibb (BMY) closed the most recent trading day at $78.28, moving -0.53% from the previous trading session.
Bristol Myers' CAR T cell therapy Breyanzi was approved by the FDA for relapsed or refractory large B-cell Lymphoma after one prior therapy.
Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Bristol-Myers...